Charles River Laboratories acquires Blue Stream Laboratories
Charles River Laboratories Acquires Blue Stream Laboratories
Charles River Laboratories International announced that it has acquired Blue Stream Laboratories, Inc. Combining Blue Stream with Charles River’s existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.
Blue Stream is an analytical contract research organization (CRO) supporting the development of complex biologics and biosimilars. Located in Woburn, Massachusetts, the company is recognized for its expertise in structural and functional protein characterization programs, and the development and validation of assays for current good manufacturing practice (cGMP) lot release and stability programs. Protein characterization is the key element for development and registration of biologic and biosimilar entities.
James C. Foster, Chairman, President and Chief Executive Officer, said, “Our continued investment in expanding our biologics portfolio, through the development of new assays and capabilities, has enabled us to provide a broader testing solution for our clients. This investment is particularly important now, when the number of biologic and biosimilar drugs in development is increasing. The acquisition of Blue Stream will meaningfully enhance the ability of our Biologic Testing Solutions business to compete effectively in this high-growth market segment.”
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Last viewed contents
Labeling proteins with ubiquitin paves new road to cell regulation research - Tipping the scales
Category:Tyrosine_kinases
Signs of dementia are written in the blood - 33 metabolic compounds linked to dementia could be key to new methods of diagnosis and treatment
Waldner strengthens its presence and service offerings in Australia
A high-yield biomass alternative to petroleum for industrial chemicals
Observing proteins in their natural environment
The pangenome - key to new therapies - Genetic diversity opens up new ways to treat life-threatening diseases
Researchers discover Achilles' heel of bacteria
Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy - Growth through investments in the “Big 3”
